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1. Introduction
Viral myocarditis is caused by a variety of viruses of more than 10 genera, such as coxsackievi‐
rus, adenovirus, parvovirus, hepatitis c virus, herpes virus, influenza virus, HIV, etc. [1]. How‐
ever, the most frequently reported and extensively studied one is coxsackievirus B3 (CVB3),
which causes ~30% of all viral myocarditis cases [2]. Thus, in this chapter the review will main‐
ly focus on CVB3-induced myocarditis. This virus can infect multiple organs of human such as
heart, pancreas, brain, liver, lung, spleen, etc. and cause myocarditis, pancreatitis, meningitis,
hepatitis, etc. However, the most fatal disease is myocarditis, particular in children and young
people [3]. Viral myocarditis is characterized by inflammatory infiltration of immune cells in
the heart muscle after viral infection. This viral infection can cause direct damage of cardio‐
myocytes as well as immune-mediated destructions of the myocardium, leading to cardiac
dysfunction.  In addition,  viral  myocarditis  often progresses into dilated cardiomyopathy
(DCM), an end-stage heart dysfunction. Patients with DCM usually require heart transplanta‐
tion [4]. There is no other treatment option at the present. Viral myocarditis is one of the major
life-threatening diseases in children. It is the cause of ~ 20% of sudden unexpected death in
young people [5]. To date, there is no specific treatment for this viral infection.
CVB3 is a positive single-stranded, non-enveloped RNA virus of the enterovirus genus of
the Picornaviridae family. Its genome is ~7.4 kb long, containing a single long open reading
frame (encoding 11 proteins) flanked by the 5’ and 3’ untranslated regions (UTRs). The 5’
UTR is 741 nucleotides (nt) long and harbors a number of cis-acting translational elements,
such as the internal ribosomal entry site (IRES) and the cloverleaf sequence [6-9], which are
crucial structures for viral translation and transcription. The 3’ UTR is a 99-nt long segment
attached with a poly-A tail. The 3’ UTR folds to form kissing-loop tertiary structures, which
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are believed to play a role in facilitating viral transcription of the negative strand of CVB3
replication intermediate [10, 11]. The viral genomic RNA can directly serve as a mRNA tem‐
plate for translation of a single long polyprotein, which is processed by viral proteases to
produce eleven individual proteins, among which four are structural proteins, VP1-VP4,
and seven are non-structural proteins including proteases 2A and 3C, as well as a RNA-de‐
pendent RNA polymerase 3D. These three enzymatic proteins play important roles in viral
life cycle and pathogenesis.
CVB3 infects cardiomyocytes by endocytosis through viral receptor CAR (coxsackie and ad‐
enovirus receptor) co-localized with tight junction proteins (e.g., occludin) [12]. It is also
known that CAR-binding site (anti-receptor) on CVB3 particle lies in the canyon on the cap‐
sid surface. Upon attachment of CVB3 particles to CAR, the receptor changes conformation
to form the viral A-particle, a product of the interactions between CVB3 and CAR, which
then allows for the release of viral RNA into host cells and begins viral translation and tran‐
scription. The observation that soluble CAR protein can function as a virus trap leading to
inactive A-particles has suggested a strategy for CVB3 therapy [13-15]. Depending on the
different combination of viral strains and mouse models in the study of CVB3 infection, a
CVB3 co-receptor called decay accelerating factor (DAF, CD55) is sometimes also necessary
for CVB3 entry into the host cells [16, 17]. Thus, genes encoding CAR and DAF are impor‐
tant candidates for study of viral tropism and rational targets for antiviral drug design.
In recent years, extensive researches have been conducted for drug development. Although
effective treatments are still not clinically available for this viral disease, some research strat‐
egies are very promising and have made exciting progresses. This chapter will first briefly
summarize the current treatments used clinically for viral myocarditis even though they are
not very specific and effective. Then we will focus on recent advances in new drug develop‐
ment, which include nucleic acid (NA)-based strategies, natural compounds, cell-based ther‐
apy, etc. We will also briefly discuss the limitations and challenges faced by the
development of such treatments.
2. Current treatments
To date, there is no clinically proven specific treatment for viral myocarditis and DCM. Pa‐
tients with DCM eventually need heart transplantation as the final option [18]. Manage‐
ments for viral myocarditis are usually supportive therapies, such as improvements in
hemodynamics with drugs used to treat other kinds of heart diseases, and application of
non-specific antiviral agents to decrease viral load. The former include administration of an‐
giotensin-converting enzyme inhibitors or angiotensin receptor blockade, beta-adrenergic
blockade, diuretics, etc. [18-20]. The latter include application of type I interferon or nucleo‐
tide analogs such as ribavirin, which was reviewed elsewhere [3, 18, 19, 21, 22]. If it is
caused by an autoimmune disorder, myocarditis would be appropriately treated by immu‐
nosuppression [18, 20]. However, the effectiveness of treatment with immunosuppressive
therapies has not reached a consensus amongst different studies. This can probably be at‐
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tributed to the difficulty of confirmation and diagnosis of the etiology and pathogenesis of
myocarditis. Thus, it is very important to distinguish between infectious and autoimmune
disease, since the same methods of treatment will not be optimal for both forms of heart
muscle diseases. The diagnostic gold standard is endomyocardial biopsies with the histolog‐
ical Dallas criteria, in association with new immunohistochemical and viral PCR analyses of
cardiac tissues [23]. In case of confirmed autoimmune-related disease and lack of detectable
viral infection, an immunosuppressive treatment combining corticoids and azathioprine
may be beneficial [24]. However, if the disease is primarily caused by viral infections, more
specific antiviral agents would be the ideal drugs of choice.
In recent years, the search for such antiviral drugs has become a new trend in drug develop‐
ment for treatment of viral myocarditis. One of the strategies for developing such antivirals
is the screening of chemical compounds, such as pleconaril, capable of interacting with pi‐
cornavirus (particularly human rhinovirus) anti-receptor to block viral entry into the host
cells [25-27]. Pleconaril functions in a mechanism similar to that of WIN compounds, by in‐
teracting with the hydrophobic amino acid residues located within the canyon floor of the
anti-receptor of host cell. Thus, it results in the blockage of the attachment of viral particles
to the host cell surface and reduces viral load in the heart [28]. Furthermore, the binding of
WIN compounds also results in increased protein rigidity and stabilizes the entire viral cap‐
sid against enzymatic degradation, so that viral uncoating and release of viral RNA into the
cytoplasm is inhibited [29, 30]. Pleconaril was initially developed for treatment of human
common cold caused by human rhinovirus, a close relative of CVB3. It also shows effective‐
ness in inhibiting CVB3 infection [31]. To avoid mutation escape induced by pleconaril, new
pleconaril derivatives have been synthesized and successfully tested against pleconaril-re‐
sistant mutants [32]. However, due to its high toxicity, pleconaril has not passed the appro‐
val by FDA of USA and is only used in a compassionate manner.
3. New strategies in drug development
3.1. Nucleic acid (NA)-based antivirals against CVB3 infection
3.1.1. Anti-CVB3 antisense oligonucleotides (ASONs)
ASONs are designed to bind to a complementary sequence in the target mRNA to form RNA-
DNA heteroduplexes. These double-stranded hybrid sequences are recognized by RNase H,
which digests the RNA strand in the duplex. Due to major problems, including instability, non-
specific delivery, and unwanted side effects of the ASONs, the structure of this molecule has
been modified extensively at different components (i.e., bases, sugar, or phosphate backbone),
and has entered its third generation. The first generation of chemical modification was de‐
signed to enhance nuclease resistance of ASON in serum [33]. The representative of such is the
phosphorothioate (PS) oligonucleotide (ON), in which one of the non-bridging oxygen atoms
in the phosphodiester bond is replaced by sulfur, intended to prevent cleavage by nucleases.
Early antiviral  PS-modified ASONs exhibited the antisense properties  of  phosphodiester
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ASONs, such as the ability to induce RNase H activation, while showing enhanced stability
[34]. Another strategy to increase the stability of ASONs is the addition of alkyl groups at the 2
position of the ribose. 2-O-methyl (OMe) and 2-O-methoxy-ethyl (MOE) substitutions sterical‐
ly shield the backbone from nuclease access, and also increase affinity to the target [35]. These
modified ASONs function mainly by blocking translation via steric hindrance of elongating ri‐
bosome but not by RNAse H-mediated cleavage. In order to retain the advantage of the RNAse
H mechanism, chimeric oligos containing both 2 unmodified and 2-modified DNAs, called
gapmers,  were  conceived.  The 2-O-alkyl  modified ASONs and mixed backbone gapmer
ASONs represent a second generation of ASON. The third generation ASONs are phosphoro‐
diamidate morpholino oligonucleotides (PMOs). PMOs have a structure in which the ribose is
replaced by a morpholine moiety and phosphorodiamidate (O-PONH2-O) linkers are used in‐
stead of phosphodiester bonds. Thus, PMOs are resistant to digestion by nucleases and are
electrically neutral. PMO-RNA hybrids do not activate RNase H. Therefore, the mechanism by
which PMOs inhibit protein synthesis is via binding the critical mRNA elements, such as the
mRNA 5’UTR or the start codon region, to prevent ribosomes from binding or scanning.
CVB3, one of the most frequently used model systems for study of viral replication and
pathogenesis, is also widely employed for evaluation of NA-based antiviral agents. The ear‐
ly investigations mainly focused on the application of the second and third generations of
ASONs. McManus and coworkers are one of the pioneer groups to study the potential possi‐
bility to inhibit CVB3 replication using ASONs. Their earliest work using regular ASONs to
target the different sites of 5’ UTR of CVB3 genome successfully mapped the IRES by in vitro
translation inhibition assay [9]. That study provided useful information for the design of
ASON for inhibiting CVB3 replication in vitro and in mouse models. Later, they used PS-
ASONs targeting the 5’ and 3’ UTRs as well as the start codon region, and found that the
oligomers targeting the 5’ and 3’ proximate ends of the CVB3 genome are the most effective
candidates to inhibit viral replication in HeLa cells. Each of these two ASONs resulted in
~80% reduction of viral particle production, which is followed by the candidates targeting
the IRES and the initiation codon region [36]. The importance of these sites for ASON bind‐
ing was further confirmed by in vivo evaluation using a murine myocarditis model, al‐
though the antiviral efficiency is not as high as that obtained from in vitro evaluation [37].
To improve the stability of the oligomers, our group designed eight PMOs targeting both
the sense and antisense strands of the CVB3 replication intermediate. To increase the effi‐
ciency of drug internalization, the PMOs were conjugated to a cell-penetrating arginine-rich
peptide. These modified ASONs were evaluated in HeLa cells and HL-1 cardiomyocytes in
culture and in a murine myocarditis model [38]. One of the oligomers, designed to target a
sequence in the 3’ portion of the CVB3 IRES, was found to be especially potent against
CVB3. Treatment of cells with this oligomer prior to CVB3 infection produced an approxi‐
mately 3-log10 decrease in viral titer and largely protected cells from virus-induced cyto‐
pathic effect. A similar antiviral effect was observed when this oligomer treatment began
shortly after the virus infection period. A/J mice receiving intravenous administration of this
oligomer once prior to and once after CVB3 infection showed an ~2-log10-decreased viral tit‐
er in the myocardium at 7 days post infection and a significantly decreased level of cardiac
tissue damage, compared to the controls [38].
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In addition to the many ASON reports, another strategy using CpG containing oligodeoxy‐
nucleotide to activate antiviral immunity has been reported [39]. The mechanism is that the
C-type of CpG oligomer can induce anti-CVB3 activity in human peripheral blood mononu‐
clear cells through the induction of synthesis of natural mixed interferons.
3.1.2. Antiviral ribozymes
Ribozymes are catalytically active small RNA (~30-100 nts) molecules that act as enzymes to
specifically cleave single strand RNA without the need of proteins. A major therapeutic ad‐
vantage of ribozymes is the ability to make them trans-acting and to confer specificity to virtu‐
ally cleave any target sequence [40]. This can be achieved by fusing the ribozyme core sequence
at the 5’ and 3’ ends with the sequences that are complementary to the target sequence.
Ribozyme as an antiviral agent has been tested for many viral infections; however, report on
anti-CVB3 has not been documented. Here, we will take HCV as an example to briefly discuss
the potential application of ribozyme for the treatment of HCV infection, as many recent re‐
ports found that HCV is a new causal agent of myocarditis [41, 42]. To investigate the potential
application of synthetic, stabilized ribozymes for the treatment of chronic HCV infection, Ma‐
cejak et al. designed and synthesized hammerhead ribozymes targeting 15 conserved sites in
the 5’ UTR of HCV RNA including the IRES [43]. It was shown that the inhibitory activity of ri‐
bozyme targeting site at nt 195 of HCV RNA exhibited a sequence-specific dose response, re‐
quired an active catalytic ribozyme core, and was dependent on the presence of the HCV 5’
UTR. In an investigation of new genetic approaches on the management of this infection, six
hammerhead ribozymes directed against a conserved region of the plus strand and minus
strand of the HCV genome were isolated from a ribozyme library that was expressed using re‐
combinant adenovirus vectors [44]. Treatment with synthetic stabilized anti-HCV ribozymes
and vector-expressed HCV ribozymes has the potential to aid in treatment of patients who are
infected with HCV by reducing the viral burden through specific targeting and cleavage of the
viral genome. Gonzalez-Carmona and colleagues used RNA transcripts from a construct en‐
coding a HCV-5'-NCR-luciferase fusion protein to test four chemically modified HCV specific
ribozymes in a cell-free system and in HepG2 or CCL13 cell lines. They found that ribozyme
(Rz1293) showed an inhibitory activity of viral translation of more than 70%, thus verifying
that the GCA 348 cleavage site in the HCV loop IV is an accessible target site in cell culture and
may be suitable for the development of novel optimized hammerhead structures [45].
3.1.3. Anti-CVB3 siRNAs
Accumulated evidence suggests that RNA interference (RNAi) plays an important role in
the antiviral defense mechanism in mammalian cells [46-49]. These findings fueled the inter‐
ests of researchers to use RNAi for antiviral drug development [49, 50].
The specificity of RNA silencing is mediated by small RNAs called short interfering RNAs (siR‐
NA) and microRNA (miRNA). Both types of RNAs are generated by processing of ribonucleas‐
es in the Dicer family, a group of class III endoribonucleases, which cleaves double stranded
non-coding RNA into fragments with a length of 21-25 nts. For siRNA, the long dsRNA or
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transgene-expressed short hairpin RNA (shRNA) are cleaved by Dicer. These RNAs are assem‐
bled into a multi-component complex, known as the RNA-induced silencing complex (RISC),
which incorporates a single strand (antisense strand) of the siRNA serving as a guide sequence
to silence the target gene [51, 52] (Figure. 1). For miRNA, this endogenous gene regulator is
processed from primary miRNA (pri-miRNA) transcripts of non-coding regions or introns of
protein-coding polymerase II transcripts. They are processed by RNase III Drosha to produce
approximately 70-nt long pre-miRNAs, which are transported into cytoplasm by exportin-5
and are cleaved by Dicer to become the functional miRNA. Similar to siRNA, they also form a
RISC with Argonaut proteins (having RNase H activity) and bind to their target mRNAs. The
modes of actions of siRNA and miRNA depend on the degree of complementation between the
siRNA or miRNA and their target sequences. siRNAs usually target coding regions by comple‐
mentary base-paring and induce sequence-specific cleavage of mRNA substrate [53]; however,
miRNAs preferentially recognize target sequences in the 3’ UTR of mRNAs and these target
sites are often in multi-copy [54-57]. The binding of the miRNAs often takes place with an in‐
complete base-pairing, although a perfect base-pairing in the seed region (positions nt 2-8 from
5 end of the antisense strand) of miRNA forms the core of interaction. Depending on the com‐
plete or partial complementarities between the miRNA and mRNA, the outcome can be cleav‐
age of the target mRNA or repression of translation (Figure. 1) [58, 59].
Figure 1. NA-based antiviral strategies to treat viral myocarditis. Antiviral nucleic acid molecules can either be
transfected into cells or expressed intracellularly. ASONs hybridize to viral mRNA to induce RNase H-mediated cleav‐
age of RNA strand of the DNA-RNA duplexes. Some modified ASONs cannot induce RNase H but they have a high
affinity for the target and inhibit translation by steric hindrance of ribosome. Binding of ribozymes to the target se‐
quence can trigger cleavage of the viral RNA. siRNAs incorporated in the RISC target the viral RNA by perfect sequence
complementation and induce cleavage of the target sequence by RNAse H activity of Ago protein. miRNAs (or AmiR‐
NAs) target viral RNA by imperfect sequence complementation and induce gene silencing by destabilizing mRNAs and
suppression of translation. In addition, siRNAs can also target cellular genes (e.g., viral receptor and signal molecules)
involved in viral entry and replication.
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RNAi-mediated antiviral strategies can achieve much higher efficiency than ASONs. Thus,
recent studies have focused on the design and evaluation of anti-CVB3 siRNAs. This group
of small double-stranded RNAs, as a silencer of target gene expression, can virtually inhibit
any genes of virus and cell if the site of targeting within the gene is unique. Thus, the target
search for anti-CVB3 siRNAs is not only concentrating on CVB3 genome but also extending
to the host cellular genes required for viral infection or replication.
3.1.3.1. Targeting the CVB3 genome
CVB3  genome  harbors  many  cis-acting  sequence  elements  for  viral  transcription  and
translation,  such  as  the  5’  and 3’  UTRs,  IRES,  and other  segments  for  binding  of  tran‐
scription  and  translation  initiation  factors.  In  addition,  the  viral  genome  also  encodes
many essential enzymes for CVB3 multiplication, such as proteases 2A and 3C as well as
the RNA-dependent RNA polymerase 3D. These structures are rational targets for design
of anti-CVB3 siRNAs. This hypothesis has been tested by a number of groups. The earli‐
er selection of the siRNA targets was focused on CVB3 protease 2A. Almost at the same
time, two groups independently found that inhibition of 2A protease by specific siRNAs
significantly  reduced  CVB3  replication.  Our  laboratory  evaluated  five  siRNAs targeting
the 5’  UTR, AUG start  codon,  VP1,  2A and 3D, respectively and found that  the siRNA
targeting 2A (nts 3543-3561) showed strongest anti-CVB3 activity in HeLa cells, resulting
in  92%  reduction  of  viral  replication  and  siRNAs  targeting  VP1,  3D  and  the  5’UTR
showed modest  antiviral  effects,  respectively.  By  mutational  analysis  of  the  mechanism
of siRNA action, we further found that siRNA functions by targeting the positive strand
of the virus and require a perfect sequence match in the central region of the target, but
mismatches were more tolerated near the 3’ end than the 5’ end of the antisense strand
[60]. This finding on the targeting of siRNA to positive strand of CVB3 was further sup‐
ported by a later study using siRNA targeting the CVB3 3D gene [61]. We later also con‐
jugated the siRNA-2A with folate to achieve specific delivery of the drug into HeLa cells
and  inhibited  CVB3  replication[62].The  second  group  that  studied  the  siRNA  targeting
CVB3  2A  by  Merl  and  co-workers  evaluated  antiviral  activity  of  siRNA-2A  (nts
3637-3657)  in  vitro  and  in  highly  susceptible  type  I  interferon  receptor-knockout  mice.
They found that siRNA-2A led to a significant reduction of viral tissue titers, attenuated
tissue injury and prolonged survival of mice [63].  It  is very interesting to point out that
although the two groups used different targeting sequences within the 2A RNA, they all
achieved  high  efficiency  of  antiviral  effects.  However,  the  later  work  by  Racchi  et  al.,
which used these two siRNAs together to transfect HeLa cells and then infect with CVB3
did not potentiate the anti-CVB3 effect compared with an equimolar concentration of ei‐
ther siRNA [64].
CVB3 RNA polymerase 3D is probably the most frequently used target for design of anti-
CVB3 siRNAs as it is the only viral enzyme involved in CVB3 RNA replication. To date, at
least a half dozen of studies on 3D have been reported. The earlier in vitro investigations
used either un-modified or LNA-modified siRNAs or plasmid vector-expressed shRNAs
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and all achieved significant reduction of viral replication in CVB3-infected HeLa or Cos-7
cells [60, 61, 65-67]. The in vivo evaluation using mouse models also showed very promising
results. One study employing transient transfection for in vivo mouse models demonstrated
that two of the six candidate siRNAs targeting 3D and VP1, respectively, exerted strong an‐
ti-CVB3 effects in viral replication, accompanied by attenuated pancreatic tissue damage
[68]. Another in vivo study is the intravenous treatment of mice with an adeno-associated vi‐
rus vector (AAV2.9) expressing a shRNA targeting 3D [69]. Intravenous injection of re‐
combinant AAV2.9 significantly attenuated cardiac dysfunction compared to vector-treated
control mice on day 1 after CVB3 infection. Recently, a study by combination of soluble CAR
receptor (sCAR-Fc) and siRNA targeting 3D achieved a synergistic effect in antiviral effect
in human myocardial fibroblast cell culture [14].
Other  less  frequently  used  CVB3  target  genes  are  protease  3C,  structural  protein  VP1
and  non-structural  protein  2C.  Like  protease  2A,  protease  3C  also  plays  an  important
role in the viral life cycle by processing CVB3 polyproteins to generate mature individu‐
al  structural  and non-structural  proteins after  initial  cleavage by 2A [70,  71].  One study
designed three siRNAs targeting genes encoding 3C, 2A and 3D of CVB4. Evaluation by
transfection of rhabdomyosarcoma (RD) cells demonstrated that siRNA-3C was the most
potent siRNA among these three in inhibition of CVB4 replication. This antiviral activity
was followed by siRNAs targeting 3D and 2A [72].  The difference in efficiency of these
siRNAs was discussed by these authors and they proposed that this may be due to dif‐
ferences in function of these viral enzymes, which are encoded by these regions. The 3C
region encodes a protease 3C which is responsible for the majority of cleavage of the vi‐
ral polyprotein [71] and 3C as well as its precursor 3CD also plays an important role at
the level of viral transcription [73]. Protease 3C has been shown to be critical for interac‐
tion with the cloverleaf structures found at the 5’ UTR of the viral genome to deliver the
3D to  the  replication complex [74].  They also indicated that  since  the  function of  3C is
required prior to 3D, a down-regulation in 3C would have a detrimental  effect  on viral
transcription, as available 3D would not be able to carry out replication of CVB4 replica‐
tion  without  the  assistance  of  3C.  The  authors’  interpretation  seems  to  be  reasonable;
however, according to the order (timing) of action for these enzymes, 2A cleaves the pol‐
yprotein prior  to  3C cleavage.  For  this  situation,  it  may be difficult  to  explain why the
siRNAs targeting 2A did not  achieve a  more efficacious anti-CVB3 activity  than siRNA
targeting  3C.  Obviously,  many  issues  relating  to  the  mechanisms  of  action  need  to  be
further studied. However, according to the present reports, one point is clear that 2A, 3C
and 3D are three important targets for design anti-CVB3 siRNAs.
Viral  structural  protein  VP1  was  also  a  selected  target  for  testing  anti-CVB3  siRNAs;
however, data from literature often showed less effectiveness of the siRNA targeting this
structural gene compared to that targeting other genes [60, 65, 68]. Due to the absence of
a proof-reading activity in 3D, the mutation rate for RNA viruses is as high as 10-3  -10-4
[75]. Thus, in recent years, the discovery of the occurrence of escape mutants due to siR‐
NA  treatment  of  HCV,  poliovirus  and  HIV  infections  [76-78]  greatly  encouraged  re‐
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searchers  to  search  for  new  approaches  to  counteract  drug  resistance.  One  direction  is
the application of multiple distinct siRNAs or a siRNA pool to target more than one tar‐
get genes of the virus [79,  80].  The other direction is the identification of conserved cis-
acting  replication  elements  (CRE)  [81].  Theoretically,  the  5‘  and  3‘  UTRs  are  the  ideal
target  regions  for  siRNAs  as  they  harbor  a  number  of  conserved  cis-acting  elements.
However, studies with poliovirus and CVB3 found that siRNA residing in these regions
are less efficient than siRNAs targeting other regions (e.g., the coding region and particu‐
larly the non-structural coding region) in inducing antiviral activity [60, 77, 79, 82].  This
low antiviral potency seems to be due to the highly ordered structure of the UTRs itself,
as  well  as  to  the  formation  of  the  protein-RNA  complexes  in  the  region,  which  may
block the access of the RISC complexes to its target sequences. To address this issue, Lee
and coworkers selected a CRE within the coding region of 2C. Evaluation in HeLa cells
demonstrated the down regulation of virus replication and attenuation of cytotoxicity in
various  strains  and human isolates.  Cells  treated with  this  siRNA were  resistant  to  the
occurrence  of  viable  escape  mutants  and  showed sustained  antiviral  ability  [83].  Based
on this  study,  a  similar  experiment  using siRNA targeting CRE of  CVA24 2C was con‐
ducted and the  authors  reported similar  observations  [84].  These  findings  from in  vitro
studies were further strengthened by in vivo  evaluation, in which recombinant lentivirus
was employed to express shRNAs targeting the CRE of CVB3 2C. Mice injected intraperi‐
toneally with recombinant lentiviruses had significant reductions in viral titers, viral my‐
ocarditis  and proinflammatory  cytokines  as  well  as  improved survival  rate,  after  being
challenged with  CVB3 [85].  Recently,  this  CRE was  further  confirmed for  a  number  of
enteroviruses, by using a novel program and in vitro evaluation [86].
3.1.3.2. Targeting host cellular genes
Another  approach to  fight  drug resistance caused by escape mutants  is  the  selection of
therapeutic targets within the host cellular genes that are involved in virus entry or viral
replication. In this regard, the CAR receptor which is shared by CVB3 and adenovirus is
an attractive candidate since both CVB3 and adenovirus are considered as  the common
causal agents of myocarditis. To date, two studies have been reported to silence CAR ex‐
pression with  specific  siRNAs.  One study reported that  transfection  of  HeLa cells  with
siRNAs, siCAR2 or siCAR9, almost completely silenced the expression of CAR and that
further  analysis  by viral  plaque assay revealed ~60% reduction of  CVB3 particle  forma‐
tion [67].  Another study, using cardiac-derived HL-1 cell  line and primary neonatal car‐
diomyocytes  (PNCMs)  demonstrated  that  treatment  with  recombinant  adenoviruses
expressing shRNAs against CAR resulted in almost completely silencing of CAR expres‐
sion in both HL-1 cells and PNCMs. CAR knockout resulted in inhibition of CVB3 infec‐
tions by up to 97% in HL-1 and up to 90% in PNCMs. Adenoviruses were inhibited by
only 75% in HL-1, but up to 92% in PNCMs [87].
Another host gene,  the tissue inhibitor of matrix metalloproteinase-1 (TIMP-1),  has been
suggested  to  be  a  potential  target  for  siRNA  to  ameliorate  CVB3-induced  myocarditis.
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This suggestion is based on the investigation of Crocker and colleagues on a new role of
TIMP-1  in  exacerbating  CVB-induced  myocarditis.  They  found  that  TIMP-1  expression
was induced in the myocardium by CVB3 infection. Surprisingly, TIMP-1 knockout mice
exhibited a  profound attenuation of  myocarditis,  with increased survival.  The ameliora‐
tion of  disease in TIMP-1 knockout mice was not attributable to either an altered T-cell
response to the virus nor to reduced viral replication. These data allowed the authors to
propose and prove a novel function for TIMP-1. Its highly localized up-regulation might
arrest the matrix metalloproteinase (MMP)-dependent migration of inflammatory cells at
the sites of infection, thereby anatomically focusing the adaptive immune response. Final‐
ly,  the  benefits  of  TIMP-1  blockage  in  treating  CVB3-induced  myocarditis  were  con‐
firmed  by  administration  of  siRNAs  targeting  TIMP-1,  which  diminished  the  disease.
However,  this  improvement  of  the  treatment  is  not  due  to  changes  of  viral  titers,  as
demonstrated by viral plaque assay [88].
Recently, active investigations on CVB3-induced signal transduction pathways have pro‐
vided new avenues for the search of therapeutic targets for the treatment of myocarditis.
Since CVB3, like other picornaviruses,  requires the activation of certain signal pathways
for initiating their  life  cycle,  inactivation of  some signal  molecules in the signal  cascade
with specific siRNAs would block CVB3 replication. Such kind of studies that have been
documented  thus  far  include  i)  the  knockdown  of  ubiquitin  expression  by  siRNAs  to
down-regulate  the  ubiquitination  and  subsequent  alteration  of  protein  function  and/or
protein  degradation  [89];  ii)  silencing  of  proteosome activator  REG to  inhibit  the  REG-
mediated degradation of  several  important  intracellular  proteins  [90],  such as  cyclin-de‐
pendent  kinase  inhibitors  p21,  p16  and  tumor  suppressor  p53;  and  iii)  knockdown  of
genes  critical  for  autophagy  formation  including  ATG7,  Beeclin-1  and  VPS34  [91].  Al‐
though these target  genes mentioned above have been tested in vitro  using specific  siR‐
NAs  in  signal  transduction  studies  and  showed  promising  outcomes,  their  potential
serving as a therapeutic  target  for treatment of  CVB3 infection needs further evaluation
by pharmacological study in animal models.
3.1.4. Anti-CVB3 artificial miRNAs
miRNAs are a group of recently discovered new regulators of gene expression. These en‐
dogenous regulators control one third of human gene expression [92, 93].  Thus, endoge‐
nous miRNAs are  important  targets  for  gene therapy and artificial  miRNAs (AmiRNA)
are useful tools for inhibiting disease-causing gene expression [94,  95],  which have been
tested in numerous studies on the treatment of  cancers,  cardiovascular diseases,  genetic
diseases  and  other  viral  infections.  To  test  its  anti-CVB3  effect,  we  constructed  three
short  hairpin  AmiRNAs  (AmiR-1,  -2  and  -3)  targeting  the  stem-loop  of  the  3’  UTR  of
CVB3 with mismatches at the middle region of the target [96]. Transfection of HeLa cells
showed over-expression of these mature AmiRNAs as determined by real time quantita‐
tive  RT-PCR.  After  these  AmiRNA-expressing  cells  were  infected  with  CVB3,  the  viral
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titers were reduced ~10 folds in cell  cultures treated with AmiR-1 or AmiR-2 but not in
those  treated  with  AmiR-3,  at  24  h  post  infection.  Mutational  analysis  of  the  targeting
sites of AmiRNAs demonstrated that the central region but not the seed region of AmiR‐
NAs is more tolerant to target mutation. In this study we also performed targeted deliv‐
ery of the AmiRNAs to host cells through ligand-receptor interactions. Recently, another
group evaluated the  antiviral  activity  of  miR-342-5p in  CVB3 infection of  tissue culture
cells.  They  found  that  miR-342-5p  functions  by  targeting  CVB3  2C  region  at  nts
4989-5010,  which is  conserved in CVB type 1-5.  Treatment of  HeLa cells  by transfection
significantly inhibited viral RNA and protein synthesis. Mutation of the target site or us‐
ing inhibitor of miR-342-5p decreased the antiviral effect in vitro [97].
In summary, the NA-based antivirals against CVB3 infection discussed above have shown
great promise thus far (Table 1); however, none of them has reached the step for clinical tri‐
al. Many limitations such as drug stability, toxicity and targeted delivery need to be over‐
come before its addition to the list of clinical application.
4. Immunomodulatory therapy
As discussed above, the effectiveness of immunosuppressive therapy for viral myocarditis is
controversial; we here focus the immunomodulatory therapy on immunoglobulin (Igs)
treatment and immunoadsorption.
4.1. Immunoglobulin treatment
IgGs have already been shown to be efficacious treatments for Kawasaki disease [98], idio‐
pathic thrombocytopenic purpura, and numerous neuroimmunologic disorders including
Guillain-Barre syndrome [99]. The rationale to use IgG in viral infections results from their
antiviral and immunomodulating effects. In the setting of viral myocarditis, IgGs can be uti‐
lized to suppress superfluous immune activation which may include an autoimmune com‐
ponent, but such treatment has shown conflicting results. IgGs prevented myocardial injury
in experimental models of myocarditis [100, 101]. Even when administered in a delayed
manner, IgG administration was able to limit scar formation and improve left ventricular
(LV) function [101] or reduced pro-inflammatory TNF-α coupled with increased anti-inflam‐
matory interleukins-1 and -10 [102]. More recently, Kishimoto et al [103] also showed im‐
proved heart function in adults with myocarditis and DCM. The same group recently
showed that immunoglobulin treatment ameliorates myocardial injury in experimental au‐
toimmune myocarditis associated with suppression of reactive oxygen species [104]. To
date, however, there has only been one randomized clinical trial investigating IgG treatment
in patients with myocarditis. McNamara et al [105] showed that, in a placebo-controlled pro‐
spective trial in patients with recent-onset DCM and myocarditis, intravenous immunoglo‐
bulin administration did not improve LV function.
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Category Target Model system Delivery route Reference
PS-ASON 5’ & 3’UTRs, IRES, startcodon HeLa cell, mice Transfection Wang 2001 (36)
PS-ASON 3’end of CVB3 HL-1 cells, mice Transfection, IVinjection Yuan 2004 (37)
MOP-ASON 5’ & 3’UTRs, IRES, startcodon, minus strand HeLa, HL-1 cell, mice
Transfection, IV
injection Yuan 2006 (38)
CpG
oligomer no PBMCs Treatment Cong 2007 (39)
siRNA 2A, VP1, 3D HeLa cells Transfection Yuan 2005 (60)
siRNA 2A HeLa cells pRNA vector Zhang 2009 (62)
siRNA 2A HeLa cells, mice HydrodynamicTransfection Merl 2005 (63)
siRNA 2A HeLa cells Transfection Racchi 2009 (64)
shRNA 3D HeLa cells
Transfection of
double expression
plasmid
Schubert 2005 (66)
siRNA 3D, VP1 HeLa cells Transfection Ahn 2005 (65)
LNA-siRNA 3D Cos-7 cells Transfection Schubert 2007 (61)
siRNA siRNA pool LLC-MK2 cells Transfection Nygardas 2009 (80)
shRNA VP1, 3D, 5’ & 3’UTR Cos-7 cells, mice HydrodynamicTransfection Kim J-Y 2008 (85)
siRNA &
sCAR-Fc 3D HMF Transfection Werk D 2009 (14)
shRNA 3D HeLa, PNCMs, mice Transduction, IV, AAVvector Fechner 2008 (69)
siRNA (CVB4) 3D, 3C, 2A RD cells Transfection Tan , 2010 (72)
shRNA 2C Mice IP injection, lentivirusvector Lee 2007 (83)
shRNA
(CVA24) 2C HeLa, HCC
Transfection of
plasmid Jun 2008 (84)
siRNA
(entero-
viruses)
2C HeLa, Vero cells Transfection Lee 2009 (86)
shRNA CAR HL-1, PNCMs Adenovirus vector Fechner 2007 (87)
siRNA TIMP-1 Mice IV injection Crocker 2007 (88)
siRNA CAR, 3D HeLa,Cos-7 cells Transfection Werk 2005 (67)
siRNA Ubiquitin HeLa cells Transfection Si 2008 (89)
siRNA ATG7, Beclin-, VPS34 HeLa cells Transfection Wong 2008 (91)
siRNA Proteasome activatorREGγ HeLa cells Transfection Gao G 2010 (90)
Table 1. NA-based agents for the treatment of CVB3 infection
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4.2. Immunoadsorption
The rationale for immunoadsorption is to lower concentration of cardiotoxic antibodies in
patients plasma, and with serial treatments over 5 or more days, extract antibodies and im‐
mune complexes from the heart as well [106]. There is evidence that removal of circulating
antibodies against cardiac proteins by immunoadsorption in DCM improved cardiac func‐
tion [107] and reduced clinical and humoral markers of heart failure severity [108, 109] as
well as improved hemodynamic parameters [110]. Further immunoadsorption decreased
myocardial inflammation. In patients with inflammatory cardiomyopathy, LV systolic func‐
tion improved after protein A immunoadsorption [111]. Recently, Nagatomo et al reported
that immunoadsorption using IgG3-specific tryptophan column for patients with refractory
heart failure due to DCM is a safe treatment and has shown short term efficacy. Long term
follow-up is needed to confirm the effects on cardiac function and on morbidity/mortality in
such patients [112]. Another recent study demonstrated that immunoadsorption treatment
improved endothelial function in patients with chronic inflammatory DCM. This effect is as‐
sociated with a significant drop in circulating microparticles [113].
5. Antiviral treatment
5.1. Compounds inhibiting viral replication
As mentioned earlier,  ribavirin  is  a  frequently  used antiviral  agent.  This  agent  is  a  nu‐
cleoside analogue and can block viral  transcription elongation and thus  can be  used to
inhibit a number of RNA viral infections, including CVB3 [114, 115]. Recently, new anti‐
viral  compounds  have  been  synthesized.  Harki  et  al.  synthesized  some  cytidine  ana‐
logues and one of  them, 5-nitrocytidine,  decreased CVB3 titer  in infected cells,  with 12-
fold  higher  efficiency  than  ribavirin,  but  so  far  the  in  vivo  evaluation  has  not  been
reported [116]. Other strategies for antiviral compound design are inhibitors of viral pro‐
tease,  RNA-dependent  RNA polymerase  or  other  nonstructural  proteins,  such as  guani‐
dine  hypochloride,  HBB,  MRL-1237  and  TBZE-02,  which  interact  with  viral  2C  protein
resulting in inhibition of viral RNA transcription.
Nitrooxide (NO) donor is another form of antiviral agents interfering with viral nonstructur‐
al proteins. They inhibit enterovirus proteases 2A and 3C [109, 117]. The NO donors nitro‐
glycerin (GTN) and isosorbide dinitrate (ISDN) can suppress CVB3 replication by inhibiting
viral proteases in vitro. Further, in vivo study showed that GTN significantly reduced myo‐
carditis after administration by decreasing immune cell infiltration and tissue fibrosis up to
14 day post infection [111]. In another study using a CVB3 myocarditis mouse model, treat‐
ment with NO-metoprolol showed enhanced therapeutic benefit compared to metoprolol,
with significant reduction of viral RNA synthesis, body weight loss, infiltration and fibrosis
score [118]. Interestingly, another study using cinnamaldehyde, which can reduce plasma
nitric oxide (NO) content, also showed the effectiveness in treatment of CVB3 myocarditis.
This compound also reduced NF-κB, inducible nitric oxide synthase and TLR4 expression.
Thus, the underlying mechanism is likely by inhibiting the TLR4-NF-κB signal transduction
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pathway [119]. Recently, a protein-based CVB3 protease 3C inhibitor, 3CPI, demonstrated
that treatment by way of a micro-osmotic pump delivery significantly inhibited viral prolif‐
eration, and attenuated myocardial inflammations, subsequent fibrosis, and CVB3-induced
mortality in vivo [120].
5.2. Interferons (IFNs)
IFNs are critical cytokines of the innate immune response released in response to stimuli
with particular importance in viral infection. IFN signal through one of two receptor groups
which dictates their subtype IFN-alpha and IFN-beta are of type I and IFN-gamma is of type
II. Type I IFNs trigger critical antiviral responses whereas, type II IFNs contribute to im‐
mune enhancement and modulation including an important role in macrophage activation.
The best studied of these proteins is the IFN-gamma. Infections in IFN-gamma-deficient
mice showed that IFN-gamma triggers release of IL-1, IL-4 and transforming growth factor,
the latter being sentinel to development of cardiac fibrosis [121]. Notably, expression of IFN-
gamma by IFN-gamma recombinant CVB3 vector protected mice against infection of lethal
CVB3H3 variant by decreasing the viral load and spread as well as tissue destruction when
given prior to or directly after viral infection [122, 123].
Type I IFNs have also shown promise in the treatment of viral myocarditis. IFN-alpha is
known  to  trigger  a  number  of  biological  cascades  to  inhibit  virus  infection.  IFN-alpha
was  used  successfully  to  treat  two  patients  with  acute  enterovirus-induced  myocarditis
[123].  As  well,  IFN-beta  therapy  has  been  used  to  improve  the  prognosis  for  patients
with  DCM [124].  Recently,  experimental  evidence  has  suggested  that  IFN-beta  can  also
be  used  as  an  antiviral  treatment  and  can  improve  outcome  in  viral  myocarditis  [125,
126].  These  studies  showed  that  treatment  with  IFN-beta  resulted  in  an  elimination  of
cardiac  viral  load,  protected cardiomyocytes  against  injury  and decreased inflammatory
cell  infiltrates.  In  a  placebo  controlled,  randomized,  double-blind,  phase  II  trial  (BICC-
study),  143  patients  with  inflammatory  DCM  and  viral  myocarditis  were  treated  with
IFN-beta-1b and showed significant reduction of viral load (enterovirus) in myocardium;
however,  complete  viral  elimination  (parvovirus  B19)  was  not  achieved  in  all  patients
[127]. This is probably due to that this virus responds less well upon IFN-beta treatment.
Novel  IFN amplification using poly(inosinic  acid)-poly(cytidylic  acid)  [poly(IC)],  IFN-al‐
pha-2b,  pegylated  IFN-alpha-2b  (PEG-INTRON-alpha-2b),  and  ampligen  have  proved
successful in blocking virus infection [128].  Oral administration of IFN-alpha-2b express‐
ing  bacteria  (B.  longum)  also  protects  mice  against  CVB3-induced  myocarditis  [129].  In
addition,  type  I  interferons  induced  by  modified  3p-siRNA  specifically  targeting  CVB3
genome significantly reduced viral load and damage of the heart [130].
5.3. Soluble receptor analogues
Another similar strategy in developing antiviral agents is to block viral entry by utilization
of recombinant soluble protein of CAR receptor. Detailed review can be found in a recent
article [21]. Soluble receptor analogues bind to the virus before the viral binding to its recep‐
tor, thus preventing binding of virus and subsequent entry to the target cells. Several re‐
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search groups designed and produced this type of analogues by recombinant DNA
technology to increase its efficiency. The most common strategy is the modification of the
protein by fusion of virus binding domain on the receptor, CAR or DAF, with the C-termi‐
nus of the human IgG1 Fc region, resulting in a dimeric antibody-like molecule. This modifi‐
cation greatly enhanced the solubility and stability of the fusion protein [13, 15, 131-133]; as
well as increased the efficiency in viral neutralization [134]. However, one study reported
the possible side effects caused by this approach, which demonstrated that after treatment
with recombinant CAR4/7, animal showed aggravated myocardium inflammation, tissue
damage and presence of CAR-specific antibody. The possible mechanism leading to this
problem may be due to the bacteria-produced recombinant protein altered the glycosylation
pattern and increased the immunogenicity [135]. Recently, another study simultaneously
applied soluble CAR-Fc and siRNA targeting CVB3 genome exerted synergistic antiviral ac‐
tivity in the treatment of a persistently infected cardiac cell line in vitro [14].
6. Natural products
Natural products occupy tremendous chemical structural space – unmatched by any oth‐
er small molecule families – possess a range of biological activities, remain the best sour‐
ces  of  drugs  and  drug  leads,  and  serve  as  outstanding  small  molecule  probes  for
dissecting fundamental biological processes [136, 137]. Natural products are evolutionari‐
ly optimized to be drug-like. They are generally more potent and specific than synthetic
molecules,  suggesting  increased  binding  affinities  for  their  cognate  protein  receptors.
This characteristic may be attributed to the fact that natural products are biosynthetically
made through repeated interaction with modulating enzymes; thus their ability to inter‐
act  with biological  macromolecules is  intrinsic to their  structures.  In addition,  they may
result from a complex evolutionary interaction between co-occupants of an ecological ni‐
che, resulting in the optimization of natural products in a process that is inaccessible to
synthetic compounds [138-140].
The natural products, such as Astragalus membranaceus, Salviae miltiorrhizae, Sophorae flaves‐
centis and Phyllanthus emblica or Chinese proprietary medicines, such as Shenmai, Shuan‐
ghuangkian and Qishaowuwei, have been long known to be effective in treating viral
myocarditis. However, the components of the medicine and the mode of action are largely
unknown [141]. Recent years, emerging studies focused on the isolation of the major compo‐
nent of the medicine and the mechanisms of action. Astragaloside IV is probably the most
studied natural compound in anti-myocarditis caused by viral infection. Two groups isolat‐
ed this compound from Astragalus membranaceus and Radix Astragali respectively and all
showed the effectiveness of this component in treatment of CVB3 infection of the heart. One
group demonstrated that treatment could significantly decrease virus load, mononuclear
cell infiltration and cardiomyocyte injury in mice. They further found that astragaloside IV
exerted antiviral effects against CVB3 by upregulating IFN-gamma expression [142]. The
other group showed that astragalus treatment significantly decreased the fibrosis of the
heart tissue and increased the mouse survival rate; further analysis revealed that this cardio‐
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protective effect is largely due to the inhibition of the TGF-beta 1-Smad signaling in DCM
[143]. Sophoridine, an alkaloid extracted from Sophora flavescens, has been evaluated in mice
and rats. The results showed that sophoridine treatment obviously decreased viral titer and
enhanced mRNA expression of IL-1 and IFN-gamma but decreased TNF-alpha. They con‐
cluded that sophoridine itself but not its metabolites is responsible for its antiviral activity
by regulating cytokine expression [144]. Recently, another natural product phyllaemblicin B,
the main sesquiterpenoid glyside isolated from roots of Phyllanthus emblica, was reported to
reduce CVB3-iduced apoptosis both in vitro and in vivo. In CVB3 myocarditis mouse model,
this compound reduced CVB3 titer, decreased activities of LDH and CK in murine serum,
and alleviated pathological damage of the myocardium [145].
7. Cellular cardiomyoplasty
The critical loss of functional cardiomyocytes causes a severe deterioration of contractility,
which eventually results in heart failure. To reverse the myocardial injuries in disease pro‐
gression, the damaged, hypocontractile and necrotic myocytes need be replaced. Although
in contrast to the long-standing dogma that mammalian heart loses capability of prolifera‐
tion in injuries after birth, there is much evidence now to support a degree of regeneration
in postnatal human heart. Regardless of whether the proliferating myocytes are derived
from the resident cardiomyocytes or circulating stem cells, it is obvious that this self-renew
mechanism is not sufficient in amount to prevent or block the heart failure.
Cellular cardiomyoplasty (CCM) is now emerging as one of the most promising therapeutic
techniques for the augmentation and regeneration of injured myocardium [146]. The strat‐
egy is to introduce less differentiated or undifferentiated cells, or in vitro derived cardio‐
myocytes into injured heart to mediate repair of chronically injured myocardium [147]. Cells
of various origins and stages of differentiation, but with the capability of differentiating into
a contractile phenotype have been utilized. The most frequently referred cell types for such
treatment are skeletal myoblast, embryonic stem cells, and bone marrow cells which contain
lineages of hematopoietic and mesenchymal stem cells [148].
All transplanted cell lines mentioned above showed some improvements on myocardial re‐
gional and/or global function in a variety of animal models and some have been investigat‐
ed in clinical trials. Although the mechanism of improved cardiac function with implanted
cells requires further study, the following evidence may help us to understand the general
therapeutic process: i) systolic contraction generated by implanted cardiomyocytes; ii) alter‐
ation and attenuation of deleterious ventricular remodeling; iii) induction of angiogenesis
by released growth factors such as vascular endothelial growth factor, basic fibroblast
growth factor, and angiopoietin-1.
To date,  a  number  of  studies  have  been conducted for  the  treatment  of  myocardial  in‐
farction or chromic myocardial  ischemia,  only a few experimental  cell-based studies are
directed at treating nonischemic cardiomyopathy [149, 150]. The treatment studies for vi‐
rus-induced viral  myocarditis  or  DCM is  even fewer.  Here  we only  found two reports
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on  the  CVB3-induced  myocarditis.  The  pioneer  work  by  van  Linthout  and  co-workers
demonstrated that mesenchymal stem cells (MSCs) are potential therapeutic cells for the
CVB3-viral  myocarditis  [151].  This  finding is  largely based on that  these cells  express  a
low level of CAR receptor and thus are not sensitive to CVB3 infection. In co-culture ex‐
periments  with  the  cardiomyocytes  HL-1,  MSCs  reduced  CVB3-induced  cell  apoptosis
and  oxidative  stress.  Furthermore,  MSCs  diminished  viral  progeny  release  by  approxi‐
mately  5-fold.  Importantly,  intravenous  injection  of  MSCs  decreased  cardiac  apoptosis
and improved LV function  in  a  murine  CVB3 myocarditis  model.  A  detailed  study on
the  mechanism  revealed  that  the  protective  effect  of  MSCs  is  mediated  in  an  NO-de‐
pendent manner and requires priming via IFN-gamma. Another recent study using car‐
diac-derived  adherent  proliferating  cells  (CAPs)  showed  similar  results  as  that  using
MSCs  [152].  CAPs  only  minimally  express  both  CAR and  DAF receptors,  which  trans‐
lates  to  minimal  CVB3 copy numbers,  and without  viral  particle  release  after  infection.
Co-culture  of  CAPs  with  CVB3-infected  HL-1  cells  resulted  in  a  reduction  of  CVB3-in‐
duced HL-1  cell  apoptosis  and viral  progeny release.  In  addition,  CAPs have  immuno‐
modulatory  feature  and  can  lead  to  a  decrease  in  CVB3  load,  myocyte  death  and  an
improvement in LV contractility parameters in murine acute CVB3 myocarditis. CAPs ex‐
ert protective effects in an NO-and IL-10-dependnet manner and require IFN-gamma for
their activation.
Despite many questions regarding stem cell plasticity have not been answered, exploratory
clinical trials are currently underway with both skeletal myoblasts [153, 154] and bone mar‐
row-derived cells [155, 156]. It is estimated that more than 15 patients have been treated
with CCM worldwide, and the number of patients treated with autologous skeletal myo‐
blasts is equivalent to those treated with bone marrow cells [156]. These preliminary results
of CCM are encouraging. However, the potential for this treatment will heavily depend on
conducting more rigorously controlled and randomized clinical trials with appropriate end‐
points to show a clear therapeutic benefit of this approach. In addition, for CCM to become
a widely accepted therapy in the future, fundamental questions such as best cell source, ap‐
propriate cell dose, timing of implantation, optimum delivery mode, mechanism of action,
electrical and mechanical integration, cell survival and long term fate of transplanted cells,
need to be addressed.
8. Concluding remarks
Since the last decades, a number of new strategies have been emerged in drug develop‐
ment for treatment of viral myocarditis and its sequela DCM, which are summarized in
Figure  2.  As  myocarditis  can  be  induced  by  a  number  of  viruses,  rapid  and  timely
pathogen identification is  critically important  for  guiding early and targeted treatments.
Certainly,  rapid,  sensitive and specific  detection of  a  particular  virus or  even viral  sub‐
type  in  human  samples  by  detection  of  virus-specific  genes  would  facilitate  targeted
treatments. This is particularly crucial for the treatments using nucleic acid-based antivi‐
ral agents targeting viral RNA.
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Figure 2. Antiviral strategies for CVB3 infection. The potential therapeutic targets in viral life cycle and the subse‐
quent inflammatory response are indicated for different antiviral agents.
As CVB3 is a RNA virus and has a high mutation rate, drug resistant mutations pose poten‐
tial obstacles. Therefore, drug targeting on viral proteins for viral replication is another
choice for drug design. For example, the inhibition of RNA-dependent RNA polymerase or
proteases of CVB3 may offer great promise since their functions are essential for the virus
but not for the cell. In the treatment of infection using nucleic acid-based antiviral agents,
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simultaneous application of several drugs may achieve synergistic effects and also reduce
the emergence of drug resistance. In addition, combination with the non-nucleic acid-based
drugs, such as interferon or soluble receptor, may also achieve the same goal. Recent emerg‐
ing of the artificial microRNA technology provides another strategy for overcoming drug re‐
sistance because miRNA targeting requires partial complementation and is more tolerant to
target mutation than siRNA. In searching for new antiviral drugs, although the natural
products have long been known to be valuable sources of such agents, progresses in this
area of research are not significant as compared to other areas of drug development. Thus
more efforts should be made in the screen of the natural antiviral compounds. For end-stage
therapy, in light of the preliminary clinical studies, CCM is no doubt an exciting area. We
look forward with great anticipation to future clinical studies and a greater understanding
of the mechanism of action, which will potentially lead to clinical applications.
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